"One strike" .. a promising strategy in the treatment of cancer

Scientists from the US “Scripps” Research Institute have unveiled a new promising strategy to improve the effectiveness of the treatment of some types of cancer, including “lymph nodes”, which include an innovative mix of immunosuppressive “Roxolanip”, with “checkpoints”. Treatment with checkpoints is a form of treatment that improves the body’s immune system to fight cancer; This type of treatment uses medicines that occur certain proteins on the surface of immune cells and cancer cells that play a decisive role in regulating the immune response, which prevents them from becoming very aggressive and attacking healthy natural cells. These proteins, known as “checkpoints”, are manipulated by cancer cells to avoid immune suppressing detection; By obstructing these checkpoints, the immune system can identify cancer cells and destroy them more effectively. Despite its success, the checkpoint brakes do not work with all patients or all types of cancer, and the researchers strive to improve their efficiency and expand their application; Here comes the role of the innovative composition with “Roxolinip”, according to what was published in the study in the magazine “Science”. And “Roxolinip”, an immune suppressing agent that is traditionally used to treat “metal fibrosis”, is a disorder characterized by excessive production of blood cells by obstructing signals known as Jak Stat, playing a leading role in organizing immune responses and infections. The strategy of a single strike for cancer treatment and the research conducted by the “Scripps” team has shown that the combination of “Roxulinib” and the “inspection points” inhibitors can lead a symmetrical effect, increasing the comprehensive immune response to cancer cells. The ‘one -strike’ approach is to improve the immune effects of “Roxolinip”, to stimulate the immune system, followed by the activation of “checkpoints” inhibitors, to unleash a more powerful attack and target cancer cells. These results were supported by a clinical trial of the first phase of patients with “Limpoma Hodgkin” cancer, and the co -author of the study “John Tigaro” says that there are many activities in developing the next generation of immune treatments, and we look forward to the treatments targeting T -cells. T -cells are produced by the immune system to fight infections, as well as cancer, and patients often stop responding to immunotherapy when their t -cells begin to fade, and this phenomenon, which is called depletion of T -cells, occurs when the cells are chronic to cancer cells. Calm the immune system. Jak -enzymes are an important part of a series of reactions between cells and proteins needed for the development of immune cells, and the non -regulation of the road is related to both inflammation and cancer; Jak -brakeers limit signals that are believed to cause inflammation, which results in the immune system ‘calming down’. “The research began 11 years ago, when we originally discovered that the blockage of the inflammatory molecules that sends signals through the Jak/Stat road road can improve immune response and accelerate the process of removal of viruses … and although jak inhibitors are usually used to treat inflammatory diseases, there is a genetic link between Jak mutations and cancer.” The researchers conducted experiments on mice suffering from different forms of cancer and continuous viral infections, and they found that combining “Roxulinib” compared to the treatment with “checkpoints” alone increased the number of T -cells and normal killer cells (NC), which is a type of immune cell that limits the distribution of cancer. With this, the team worked together in front of clinical data with ‘Veronica Bachunova’ with a doctorate in medicine, and a doctorate at the University of Minnesota, who began the first phase of the clinical experiment of 19 patients with lymphomatic cancer who could not respond to the checkpoint inhibitors. The strengthening of T -cells and clinical trials showed two years after the start of a treatment system that combines “Roxolinip” and the “Nifolomab” checkpoint, 87% of patients survived, and 46% stopped showing the signs of cancer development. The flatterers are a kind of immune cell found in the bone marrow, one of the most important body defense lines against the infection, but the cells, but the cancer has often hijacked the wittens, leading to the growth of the tumor. The effectiveness of “Roxolanip” in the treatment of cancer, and they also design clinical trials to test the effectiveness of “Roxolinip” with “checkpoints” in other forms “Roxolinip”, and the checkpoint inhibitors, the ability to significantly increase the ability of the immune system to fight cancer. This new approach also emphasizes the importance of understanding the accurate environment of the crop and the treatment of improving the results of the treatment, and with continued research, clinical trials will be decisive to verify the validity of these results, identify optimal doses and combine different types of cancer. The researchers believe that the success of the ‘One -Strike’ strategy opens the door to further investigate complicated treatments in cancer treatment, and the researchers are likely to investigate other immune suppressing drugs associated with checkpoints to improve their effectiveness of a greater variety of cancer.